Savara Shares

Savara Shares Long-Term IMPALA-2 Data for Molgramostim in aPAP

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Savara Inc. a clinical stage biopharmaceutical company focused on rare respiratory diseases,…

Read MoreSavara Shares Long-Term IMPALA-2 Data for Molgramostim in aPAP
Flatiron Health Unveils Flatiron Telescope, an AI

Flatiron Health Unveils Flatiron Telescope, an AI Platform Delivering Oncology Insights in Minutes

Flatiron Health Launches Flatiron Telescope, a New AI Platform Delivering Oncology Insights in Minutes Flatiron Health announced the launch of Flatiron Telescope, a next-generation AI-powered platform designed to help life sciences teams and researchers find the right patients faster, assess study…

Read MoreFlatiron Health Unveils Flatiron Telescope, an AI Platform Delivering Oncology Insights in Minutes
Blank Bio

Blank Bio Announces Seed Funding and Strategic Partnership with PacBio to Advance RNA Foundation Models in Precision Oncology

Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology Blank Bio, an applied AI research lab training foundation models for RNA, announced the closing of a $7.2 million seed financing and…

Read MoreBlank Bio Announces Seed Funding and Strategic Partnership with PacBio to Advance RNA Foundation Models in Precision Oncology
Sustained Therapeutics

Sustained Therapeutics Announces Positive Phase 2 ST-01 Data in Podium Presentation at AUA 2026 Annual Meeting

Sustained Therapeutics Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual Meeting Sustained Therapeutics, Inc. a clinical-stage urologic therapeutics company advancing differentiated therapies for underserved conditions, today presented additional data from its…

Read MoreSustained Therapeutics Announces Positive Phase 2 ST-01 Data in Podium Presentation at AUA 2026 Annual Meeting
Atrandi Biosciences, a life science tools company pioneering Semi-Permeable Capsule (SPC) technology for single-cell and

Atrandi Biosciences Strengthens Leadership Team to Drive Global Adoption of Capsule-Based Single-Cell Technology

Atrandi Biosciences Expands Leadership Team to Accelerate Global Adoption of Capsule-Based Single-Cell Technology Atrandi Biosciences, a life science tools company pioneering Semi-Permeable Capsule (SPC) technology for single-cell and multiomics research, today announced the appointment of Sam Ropp, PhD, as Chief…

Read MoreAtrandi Biosciences Strengthens Leadership Team to Drive Global Adoption of Capsule-Based Single-Cell Technology
Bayer

U.S. Food and Drug Administration Grants Priority Review for HYRNUO as First-Line Treatment for HER2-Mutated Non-Small Cell Lung Cancer

U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer Bayer announced that the U.S. Food and Drug Administration (FDA) has granted HYRNUO® (sevabertinib) Priority Review status for…

Read MoreU.S. Food and Drug Administration Grants Priority Review for HYRNUO as First-Line Treatment for HER2-Mutated Non-Small Cell Lung Cancer
Turn Therapeutics Appoints Former FDA

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical and Regulatory Lead

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead Turn Therapeutics Inc. a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, announced the appointment of Stephen M. Hahn,…

Read MoreTurn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical and Regulatory Lead
Scribe Therapeutics

Scribe Therapeutics Showcases Enhanced CRISPR Gene Editing Data at ASGCT 2026

Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing Scribe Therapeutics, Inc. a biotechnology company engineering purpose-built CRISPR technologies to reshape the treatment of disease by…

Read MoreScribe Therapeutics Showcases Enhanced CRISPR Gene Editing Data at ASGCT 2026
Bojangles

Bojangles Foundation Raises $650K for Pediatric Heart Care Through Heart-Shaped Biscuit Campaign

Bojangles Foundation Raises More Than $650,000 Through Heart-Shaped Biscuits & Round-Up Campaign to Support Pediatric Heart Care and Research For the second year in a row, Bojangles and The Bojangles Foundation partnered with NFL legend Greg Olsen and The HEARTest…

Read MoreBojangles Foundation Raises $650K for Pediatric Heart Care Through Heart-Shaped Biscuit Campaign
ImmunityBio

ImmunityBio Secures Exclusive U.S. Deal with Japan BCG Laboratory to Expand Tokyo Strain BCG Supply

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States ImmunityBio, Inc. a commercial-stage immunotherapy company, announced an exclusive U.S. Development and Supply Agreement with Japan BCG…

Read MoreImmunityBio Secures Exclusive U.S. Deal with Japan BCG Laboratory to Expand Tokyo Strain BCG Supply

OBIO® and IPON Renew Multi-Year Partnership to Strengthen Ontario’s Sovereign IP Capacity

OBIO® and IPON Renew Multi-Year Collaboration to Advance Ontario’s Sovereign IP Capacity OBIO® and Intellectual Property Ontario (IPON) have renewed their memorandum of understanding (MOU) to ensure that Ontario’s next generation of companies developing innovative human health products continue to access optimal…

Read MoreOBIO® and IPON Renew Multi-Year Partnership to Strengthen Ontario’s Sovereign IP Capacity